Abstract

Basophil activation tests (BATs) can closely monitor, in vitro, a patient’s propensity to develop type I hypersensitivity reactions. Because of their high specificity and sensitivity, BATs have become promising diagnostic tools, especially in cases with equivocal clinical histories, skin prick test results, and/or levels of specific IgE to allergen extracts. BATs also are useful as tools for monitoring the effects of treatment, since oral immunotherapy (OIT) studies report a diminution in patients’ basophil responsiveness over the course of OIT. This review will discuss the BAT findings obtained before, during, and after OIT for food allergy. We will mainly focus on the association of basophil responsiveness, and alterations in basophil surface markers, with clinical outcomes and other clinical features, such as blood levels of specific IgG and IgE antibodies. The detailed analysis of these correlations will ultimately facilitate the use of BATs, along with other blood biomarkers, to differentiate short-term desensitization versus sustained unresponsiveness and to improve treatment protocols. Given the critical anatomic location of mast cells adjacent to the many IgE+ plasma cells found in the gastrointestinal tissues of allergic individuals, we will also discuss the role of gastrointestinal mast cells in manifestations of food allergies.

Highlights

  • Human and mouse studies have shown that mast cells and basophils are the primary immune effector cells in IgE-mediated food allergy [1,2,3,4]

  • Results of Basophil activation tests (BATs) assays are commonly presented as mean fluorescence intensity (MFI) of activation markers or percentage of cells that are CD63+ or CD63hi

  • When interpreting BAT data obtained from oral immunotherapy (OIT) studies it is important to keep in mind the particular representation used, as that might affect the interpretation of the data

Read more

Summary

Oral Immunotherapy and Basophil and Mast Cell Reactivity in Food Allergy

Anuya Paranjape 1,2, Mindy Tsai 1,2, Kaori Mukai 1, Ramona A. Specialty section: This article was submitted to Molecular Innate Immunity, a section of the journal

Frontiers in Immunology
INTRODUCTION
BASOPHIL RESPONSIVENESS AND CLINICAL PHENOTYPE
MEASUREMENTS OF BASOPHIL RESPONSIVENESS DURING ORAL IMMUNOTHERAPY
BASOPHIL RESPONSES AND CLINICAL OUTCOMES
Activation conditions Frequently used activation markers
Major findings with respect to time into the treatment
Tsai and
BASOPHIL RESPONSES AND SERUM IMMUNOGLOBULINS
TISSUE MAST CELLS AND ORAL IMUNOTHERAPY
CONCLUSIONS
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.